Arcutis Biotherapeutics (ARQT) Could Be 28% Undervalued As Profit And Guidance Improve

Why Arcutis Biotherapeutics Stock Is Back In Focus

Arcutis Biotherapeutics (ARQT) is drawing attention after reporting second quarter revenue of $129.86 million, a shift to net income of $15.01 million, and higher full year net product sales guidance.

See our latest analysis for Arcutis Biotherapeutics.

At a share price of $26.54, Arcutis Biotherapeutics has a 1 day share price return of 3.63%, a 90 day share price return of 29.65%, and a 1 year total shareholder return of 68.29%. These figures indicate recent momentum as investors respond to stronger profitability, higher 2026 sales guidance, and the recent change in commercial leadership announced on 5 August 2026.

If strong recent gains in Arcutis Biotherapeutics have you reassessing opportunities in healthcare, it may be a good moment to scan other dermatology and biotech names through 42 healthcare AI stocks

Recent gains in Arcutis Biotherapeutics reflect both stronger reported profitability and a higher 2026 sales outlook, set against a leadership change in commercial. Is the valuation now anchored in fundamentals, or driven more by sentiment around the story reset?

Most Popular Narrative: 28% Undervalued

The most followed narrative currently places Arcutis Biotherapeutics fair value at $36.88 compared with the recent $26.54 share price, which frames the stock as materially undervalued in that view.

Arcutis is poised to sustain and accelerate top line revenue growth through continued expansion of ZORYVE indications, targeting large, underserved populations such as pediatric atopic dermatitis and scalp psoriasis, while leveraging broadening insurance coverage and the ongoing shift away from steroid use in chronic dermatologic conditions.

Read the complete narrative.

Want to see what sits behind that growth story for Arcutis Biotherapeutics? The narrative leans on faster earnings expansion, rising margins and a richer future profit multiple. Curious which assumptions really carry the fair value to the mid $30s.

Result: Fair Value of $36.88 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Arcutis Biotherapeutics still carries meaningful risks if ZORYVE underperforms expectations, or if payer and reimbursement trends turn less supportive than analysts currently model.

Find out about the key risks to this Arcutis Biotherapeutics narrative.

Another View On Arcutis Biotherapeutics Valuation

While the consensus narrative frames Arcutis Biotherapeutics as undervalued based on future growth and analyst targets, the current P/E of 117x is far above the US Biotechs industry average of 16.7x, the peer average of 40.6x, and a fair ratio of 38.5x. That gap points to valuation risk if earnings or sentiment slip.

To see how that high multiple compares with underlying earnings power, take a closer look at the valuation breakdown through See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Arcutis Biotherapeutics pulling in both risk and reward angles, consider reviewing the data yourself and stress testing the assumptions behind 4 key rewards

Looking For More Investment Ideas Beyond Arcutis Biotherapeutics?

If Arcutis Biotherapeutics has sharpened your focus on select opportunities, now is the time to widen your search and pressure test your next few candidates.

• Spot potential outperformers early by scanning screener containing 20 high quality undiscovered gems that combine solid fundamentals with lower market attention.
• Strengthen downside protection by reviewing 79 resilient stocks with low risk scores that score well on resilience and financial risk metrics.
• Target quality at a reasonable price by filtering for 50 high quality undervalued stocks that pair healthier balance sheets with attractive valuations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com